Literature DB >> 32777106

The complex karyotype and chronic lymphocytic leukemia: prognostic value and diagnostic recommendations.

Ludovic Jondreville1, Daphné Krzisch1, Elise Chapiro1,2, Florence Nguyen-Khac1,2.   

Abstract

Chromosomal abnormalities are frequently observed in patients with chronic lymphocytic leukemia (CLL) and have prognostic value. Deletions of the short arm of chromosome 17 (and/or mutations TP53) predict resistance to chemoimmunotherapy and shorter progression-free survival after targeted therapies. Although the complex karyotype (CK) is strongly predictive of a poor prognosis in hematologic malignancies such acute myeloid leukemia or myelodysplastic syndrome, its value in CLL is subject to debate. Here, we review the literature on the CK in CLL and examine its prognostic value with different treatments. We also propose a standardized method for defining a CK in all types of hematopoietic neoplasm.
© 2020 Wiley Periodicals LLC.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 32777106     DOI: 10.1002/ajh.25956

Source DB:  PubMed          Journal:  Am J Hematol        ISSN: 0361-8609            Impact factor:   10.047


  5 in total

Review 1.  The complex karyotype in hematological malignancies: a comprehensive overview by the Francophone Group of Hematological Cytogenetics (GFCH).

Authors:  F Nguyen-Khac; A Bidet; A Daudignon; M Lafage-Pochitaloff; G Ameye; C Bilhou-Nabéra; E Chapiro; M A Collonge-Rame; W Cuccuini; N Douet-Guilbert; V Eclache; I Luquet; L Michaux; N Nadal; D Penther; B Quilichini; C Terre; C Lefebvre; M-B Troadec; L Véronèse
Journal:  Leukemia       Date:  2022-04-16       Impact factor: 12.883

2.  Increased serum level of alpha-2 macroglobulin and its production by B-lymphocytes in chronic lymphocytic leukemia.

Authors:  Regina Michelis; Lama Milhem; Evleen Galouk; Galia Stemer; Ariel Aviv; Tamar Tadmor; Mona Shehadeh; Lev Shvidel; Masad Barhoum; Andrei Braester
Journal:  Front Immunol       Date:  2022-09-02       Impact factor: 8.786

Review 3.  Heterogeneity of TP53 Mutations and P53 Protein Residual Function in Cancer: Does It Matter?

Authors:  Paola Monti; Paola Menichini; Andrea Speciale; Giovanna Cutrona; Franco Fais; Elisa Taiana; Antonino Neri; Riccardo Bomben; Massimo Gentile; Valter Gattei; Manlio Ferrarini; Fortunato Morabito; Gilberto Fronza
Journal:  Front Oncol       Date:  2020-10-28       Impact factor: 6.244

Review 4.  Treatment Approaches to Chronic Lymphocytic Leukemia With High-Risk Molecular Features.

Authors:  Lina van der Straten; Paul J Hengeveld; Arnon P Kater; Anton W Langerak; Mark-David Levin
Journal:  Front Oncol       Date:  2021-12-09       Impact factor: 6.244

5.  Chromosome banding analysis and genomic microarrays are both useful but not equivalent methods for genomic complexity risk stratification in chronic lymphocytic leukemia patients.

Authors:  Silvia Ramos-Campoy; Anna Puiggros; Sílvia Beà; Sandrine Bougeon; María José Larráyoz; Dolors Costa; Helen Parker; Gian Matteo Rigolin; Margarita Ortega; María Laura Blanco; Rosa Collado; Rocío Salgado; Tycho Baumann; Eva Gimeno; Carolina Moreno; Francesc Bosch; Xavier Calvo; María José Calasanz; Antonio Cuneo; Jonathan C Strefford; Florence Nguyen-Khac; David Oscier; Claudia Haferlach; Jacqueline Schoumans; Blanca Espinet
Journal:  Haematologica       Date:  2022-03-01       Impact factor: 9.941

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.